Skip to main content

Table 3 Genes that have a general association (P-value < 0.05) with the lifetime glioblastoma survival

From: Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival

Gene Symbol

Probe Identifier

P-value

Hazard Ratio1

Relevant literature references

Syne1

209447_at

<.0001

0.17 (0.10-0.32)

[60]O

E2f3

203692_s_at

<.0001

0.26 (0.15-0.44)

[28]G

Fstl1

208782_at

<.0001

0.31 (0.22-0.42)

[25]G

Ep300

213579_s_at

<.0001

0.34 (0.29-0.57)

[26]G

Gigyf2

212261_at

<.0001

0.39 (0.26-0.58)

n/a

Topors

204071_s_at

<.0001

0.41 (0.29-0.59)

[26]G

Chst4

220446_s_at

0.09892

0.44 (0.17-1.16)

[89]O

Sar1a

201543_s_at

<.0001

0.44 (0.29-0.66)

n/a

Il13ra1

210904_s_at

<.0001

0.47 (0.36-0.60)

[24]G

Sod2

221477_s_at

<.0001

0.47 (0.37-0.59)

[25]G

Rab15

221810_at

<.0001

0.48 (0.34-0.69)

n/a

Timm23

218118_s_at

0.0239

0.50 (0.27-0.91)

n/a

Kcnj4

208359_s_at

<.0001

0.50 (0.38-0.66)

n/a

Rpl37a

213459_at

0.0023

0.51 (0.33-0.79)

[90]G

Camk2g

214322_at

0.0135

0.53 (0.32-0.88)

[56]G

Plcg1

216551_x_at

0.0068

0.55 (0.35-0.85)

[26]G

Slc43a3

213113_s_at

0.0004

0.56 (0.40-0.77)

n/a

Cdc42

208727_s_at

<.0001

0.57 (0.45-0.73)

[26]G

Csf1

207082_at

0.0092

0.58 (0.38-0.88)

[26]G

Ccnb2

202705_at

0.0118

0.60 (0.40-0.89)

[91]G

Tlk2

212997_s_at

0.0004

0.64 (0.49-0.82)

n/a

Mtap

204956_at

0.0091

0.67 (0.49-0.91)

[26]G

Egfr

211551_at

0.07432

0.68 (0.45-1.04)

[24]G

Akt2

211453_s_at

0.0292

0.68 (0.48-0.96)

[86]G

Akr1c3

209160_at

<.0001

0.70 (0.62-0.81)

[26]G

Tp53

211300_s_at

0.0215

0.76 (0.60-0.96)

[25]G

Igf1

209541_at

0.0183

0.76 (0.61-0.95)

[26]G

Rpl10

221989_at

0.0392

0.80 (0.64-0.99)

[24]G

Arhgef4

205109_s_at

0.06472

0.80 (0.64-1.01)

n/a

Cdc42

214230_at

0.05542

0.82 (0.67-1.00)

[26]G

Chi3l1

216546_s_at

0.061

0.87 (0.75-1.00)

[70]G

Ppbp

214146_s_at

0.012

1.16 (1.03-1.30)

n/a

Cdkn2a

209644_x_at

0.0003

1.18 (1.08-1.29)

[92]G

Wdr67

214061_at

0.0237

1.30 (1.03-1.63)

[93]O

Tspyl5

213122_at

0.0003

1.34 (1.14-1.56)

n/a

Usf2

215737_x_at

<.0001

1.42 (1.19-1.69)

[94]O

Camk2g

212757_s_at

0.0078

1.54 (1.12-2.13)

[56]G

Pik3r1

212240_s_at

0.0022

1.67 (1.20-2.32)

[20]G

Akt1

207163_s_at

0.0005

1.70 (1.26-2.30)

[84]O

Rac2

213603_s_at

0.0001

1.74 (1.31-2.31)

[95]G

Six6

207250_at

<.0001

1.82 (1.45-2.28)

[96]O

Spg21

217827_s_at

0.0387

1.91 (1.03-3.52)

n/a

Wdyhv1

219060_at

0.0015

1.95 (1.29-2.94)

n/a

Uros

203031_s_at

0.0067

2.37 (1.27-4.42)

n/a

Lin7c

219399_at

0.0002

2.40 (1.51-3.80)

[97]O

Ros1

207569_at

<.0001

2.58 (1.73-3.85)

[98]O

Cdk2

204252_at

<.0001

2.74 (1.78-4.21)

[91]G

Jag2

32137_at

<.0001

2.78 (1.86-4.14)

[24]G

Kiaa0090

212395_s_at

<.0001

2.89 (1.87-4.47)

n/a

Ccnb1

214710_s_at

<.0001

3.16 (2.00-4.98)

[91]G

Scn5a

207413_s_at

<.0001

3.21 (1.79-5.74)

n/a

Col14a1

212865_s_at

<.0001

3.30 (1.93-5.63)

[99]O

Hoxa10

213147_at

<.0001

3.30 (1.93-5.65)

[100]O

Cdc42

208728_s_at

<.0001

3.94 (2.12-7.32)

[26]G

Pdcd4

202731_at

<.0001

4.68 (3.01-7.28)

[26]G

  1. n/a, No association with any type of cancer found in literature;
  2. 1 Hazard ratio estimate (95% confidence interval);
  3. 2 Borderline significant (P-value < 0.1) included for completeness;
  4. G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;
  5. O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.